EXPERIENCE
Executives & Board of Advisors
Recognized leaders with expertise in cancer and immunity, business development, and therapeutics development
Management
Paul E. Sporn, Esq.
Co-Founder & Managing Director
Paul is the co-founder of TTX and a seasoned executive and corporate attorney. He has guided the company’s organization, patent licensure, intellectual property expansion, contractor negotiations, and strategic planning. He is the former founder of General Counsel Direct Legal Services, LLC, a provider of fractional general counsel services. Over the course of a 30 plus year legal career, Paul has served as general counsel to companies in regulated industries focusing on asset protection, risk management, and complex commercial transactions.
Louis Schwartz
Chief Financial Officer
Louis manages TTX’s financial operations, supervising financial planning and forecasting, grants and contracts, audit and compliance. Louis has more than three decades of experience in international finance and management in both the public and private sectors. Before joining TTX, he served as CFO for the International AIDS Vaccine Initiative (IAVI) and was formerly vice president for finance and administration at the American Jewish World Service. He is the former CFO at the nonprofit Neighborhood Housing Services of New York City and at Troika Dialog, a Russian investment bank. He has held leadership positions in commercial banking in Moscow and New York City and is a member of the CFO Roundtable.
SCIENCE ADVISORS
John Letterio, MD
Chief Science Advisor
John is Professor of Pediatrics and Chief, Division of Pediatric Hematology/Oncology, Case Western Reserve University and Rainbow Babies & Children’s Hospital in Cleveland, OH. He serves as Co-Director of the Developmental Therapeutics Program of the Case Comprehensive Cancer Center. John’s career has been committed to the development of new and safer treatment modalities for cancer patients, both pediatric and adult. His research regarding the biology and potential therapeutic applications of synthetic triterpenoids was part of a 20-year plus collaboration with TTX founder Dr. Michael B. Sporn that started when he joined the National Cancer Institute’s Laboratory of Chemoprevention in 1991 and is continuing.
Dr. Andrew E. Place, MD, PhD.
Senior Science Advisor
Andrew is Vice President and Chief Medical Officer for the Department of Pediatric Oncology at Dana Farber Cancer Institute/Boston's Children's Hospital and an Assistant Professor of Pediatrics at Harvard Medical School. He was formerly the Chief Medical Officer at Institutional Centers for Clinical and Translational Research at Boston Children's Hospital and Associate Director of Developmental Therapeutics. His research career has been focused on developing novel therapeutics that optimize upfront therapy, improve patient outcomes, and lessen long-term toxicity. Andrew has a deep understanding of the pharmacology of synthetic triterpenoids. As a PhD candidate under the direction of TTX founder Dr. Michael B. Sporn, he was intimately involved in the preclinical development of the early generation synthetic triterpenoids that preceded 2P-Im.
BUSINESS ADVISORS
Alison C. Finger
Industry
Alison has over 30 years of experience successfully developing and commercializing brands that have changed clinical practice and patients’ lives. Therapeutic areas include Gene and Cell Therapy, Oncology, Neurology, Virology and Diabetes. She has launched products in the US, Europe, Asia and is recognized for her cross functional leadership spanning R&D, manufacturing, commercial launch, and operational P&L management. She currently serves as an Independent Director for ADMA Biologics and previously for Decibel Therapeutics, VBL Therapeutics, and as Chair of the Alliance for Regenerative Medicine Gene Therapy section.
Daniel Mudd, MPA
Business and Finance
Daniel brings 30 years’ of executive experience leading businesses, advising boards, investors, governments, and academic institutions to TTX. He is the former Senior Vice President of General Electric and former CEO of Fortress Investment Group, and was chosen to lead Fannie Mae out of the 2008 Financial Crisis, He currently advises companies in the energy, military security, real estate, health care and finance sectors.
Sigrid Usen, Esq.
Legal and Compliance
Sigrid is an accomplished attorney and executive who has represented clients across a wide variety of industries including financial services, real estate, biotechnology, and pharmaceuticals. She began her career at Sidley Austin and has an extensive background in corporate law, finance, mergers and acquisitions, securities, litigation, risk management and employment law. She was formerly Vice President and Senior Counsel/ High Yield Trading Floor Counsel at Merrill Lynch and later practiced at Skadden Arps. She is currently Assistant General Counsel and Chief Compliance Officer at The RMR Group.